ICG-001 is primarily used in research settings to study and modulate the Wnt/β-catenin signaling pathway, which plays a critical role in cell proliferation, differentiation, and tissue regeneration. It acts as a selective inhibitor of this pathway by disrupting the interaction between β-catenin and its transcriptional co-activator CBP. This mechanism makes it a valuable tool in investigating diseases where Wnt signaling is dysregulated, such as certain cancers, fibrosis, and degenerative disorders. Researchers also explore its potential in regenerative medicine, particularly in promoting tissue repair and reducing scarring. Additionally, ICG-001 has shown promise in preclinical studies for targeting cancer stem cells, which are often resistant to conventional therapies. Its applications extend to exploring therapeutic strategies for conditions like Alzheimer's disease, where Wnt signaling is implicated in neuronal health and function.